目的 探讨甲基多巴联合尼卡地平治疗妊娠期高血压的临床疗效。方法 选取2017年2月—2020年3月驻马店市中医院收治的124例妊娠期高血压患者，随机分为对照组（62例）和治疗组（62例）。对照组患者静脉滴注盐酸尼卡地平注射液，起始剂量为40 mg/次，2次/d，之后根据患者血压情况调整剂量。治疗组在对照组基础上口服甲基多巴片，0.25 g/次，3次/d。两组患者持续治疗两周。观察两组患者临床疗效，比较治疗前后两组患者血压情况、血流动力学、凝血功能，血清炎症因子白细胞介素-6（IL-6）、C反应蛋白（CRP）和肿瘤坏死因子-α（TNF-α）水平及妊娠结局。结果 治疗后，治疗组总有效率为93.55%，显著高于对照组的79.03%（P<0.05）；治疗后，两组收缩压（SBP）、舒张压（DBP）、脐血流和阻力指数较治疗前显著降低（P<0.05），且治疗组明显低于对照组（P<0.05）；心脏指数较治疗前显著提高（P<0.05），治疗组高于对照组（P<0.05）；治疗后，两组凝血酶原时间（PT）、凝血酶时间（TT）、活化部分凝血活酶时间（APTT）水平较治疗前明显延长（P<0.05），治疗组较对照组显著延长（P<0.05）；治疗后，两组患者血清IL-6、CRP、TNF-α水平低于治疗前（P<0.05），且治疗组低于对照组（P<0.05）；治疗组早产、剖宫产、产后出血、胎盘早剥、胎儿宫内窘迫、新生儿窒息发生例数低于对照组（P<0.05）。结论 甲基多巴配合尼卡地平治疗妊娠期高血压患者疗效显著，可明显降低血压，改善血流动力学，减轻炎症反应，减少不良妊娠结局。

Objective To explore the clinical effect of methyldopa combined with nicardipine in treatment of hypertension during pregnancy. Methods Patients (124 cases) with hypertension during pregnancy in Zhumadian TCM Hospital from February 2017 to March 2020 were randomly divided into control (62 cases) and treatment (62 cases) groups. Patients in the control group were iv administered with Nicardipine Hydrochloride Injection, and the initial dose was 40 mg/time, twice daily, then adjusted the dose according to the patient's blood pressure. Patients in the treatment group were po administered with Methytdopa Tablets on the basis of the control group, 0.25 g/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the blood pressure, hemodynamic index levels, coagulation function index levels, the serum inflammatory factor IL-6, CRP and TNF-α levels, and pregnancy outcomes in two groups before and after treatment were compared. Results After treatment, the clinical effective rate in the treatment group was 93.55%, which was significantly higher than 79.03% in the control group (P<0.05). After treatment, the systolic blood pressure (SBP), diastolic blood pressure (DBP), umbilical blood flow and resistance index in the two groups were significantly lower than those before treatment (P<0.05), and which in the treatment group were significantly lower than that in the control group (P<0.05), the cardiac indexes in the treatment group were significantly higher than that in the control group (P<0.05), which in the treatment group were significantly higher than that in the control group (P<0.05). After treatment, the levels of PT, TT, and APTT in two groups were significantly longer than those before treatment (P<0.05), and which in the treatment group was longer than those in the control group (P<0.05). After treatment, the serum levels of IL-6, CRP and TNF-α in two groups were lower than that before treatment (P<0.05), and which in the treatment group was lower than those in the control group (P<0.05). The cases of premature delivery, cesarean section, postpartum hemorrhage, placental abruption, fetal distress and neonatal asphyxia in the treatment group were lower than those in the control group (P<0.05). Conclusion Methyldopa combined with nicardipine has a significant effect in treatment of hypertension during pregnancy, can significantly reduce blood pressure, improve hemodynamics, reduce inflammation, and significantly reduce adverse pregnancy outcomes.

R984